SCHEMBL25062002

SCHEMBL25062002

CCCCCc1ccccc1NCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.50
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
ALOX5 P09917 1/20 0.41
PTGS2 P35354 1/20 0.41
AR P10275 1/20 0.40
PLK1 P53350 1/20 0.40
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39
G6PD P11413 1/20 0.39
KMT2A Q03164 1/20 0.39
BID P55957 3/20 0.39
MCL1 Q07820 3/20 0.39
BCL2L1 Q07817 2/20 0.39
BAK1 Q16611 2/20 0.39
KAT8 Q9H7Z6 2/20 0.39
TLR8 Q9NR97 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11262642 0.98 LIPG (0.53) LIPGADRA2BADRA2CNR1H2NR1H3
SCHEMBL29265284 0.98 LIPG (0.53) LIPGADRA2BADRA2CNR1H2NR1H3
SCHEMBL2698254 0.94 ADRA2B (0.45) LIPGADRA2BADRA2CARPOLB
SCHEMBL8679853 0.88 ADRA2B (0.53) ADRA2BADRA2CARPOLBMEN1
SCHEMBL10408672 0.87 LIPG (0.49) LIPGADRA2BADRA2CNR1H2NR1H3
SCHEMBL10409294 0.85 LIPG (0.51) LIPGNR1H2NR1H3PLK1POLB
SCHEMBL5253208 0.85 LIPG (0.47) LIPGADRA2BADRA2CNR1H2NR1H3
SCHEMBL4557996 0.85 LIPG (0.51) LIPGNR1H2NR1H3PLK1POLB
SCHEMBL8283669 0.83 POLB (0.41) LIPGADRA2BADRA2CARPOLB
SCHEMBL8761186 0.83 ADRA2B (0.40) ADRA2BADRA2CARPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230060004-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-02-23 US disclosed
CN-109912467-A A kind of synthetic method of 2- aryl phenylethylamine derivative 南昌航空大学 2019-06-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060004-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK LIPG 217/4885ADRA2B 2859/4885ADRA2C 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.